Sarepta Therapeutics, SRPT

Sarepta Therapeutics’ (SRPT) Sell Rating Reiterated at HC Wainwright
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by stock analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $75.
Sarepta Therapeutics, Inc. (SRPT): Among the Stocks That Will Go to The Moon According to Analysts
We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks.
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was 7.
Sarepta Therapeutics: Q4 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported fourth-quarter profit of $159 million. On a per-share basis, the Cambridge, Massachusetts-based company said it had net income of $1.50.
Evercore ISI Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)
Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) yesterday and set a price
Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript
And welcome to the Sarepta Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, today’s program is being recorded. At this time, I’d like to turn the call over to Mary Jenkins,
Sarepta files automatic mixed securities shelf
EST Sarepta (SRPT) files automatic mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...
Hosted on MSN4d
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
Sarepta Therapeutics, Inc. SRPT reported fourth-quarter 2024 earnings per share (EPS) of $1.50, which missed the Zacks ...
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $161.00 at Royal Bank of Canada
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target reduced by Royal Bank of Canada from $165.00 to $161.00 ...
Analysts Are Bullish on Top Healthcare Stocks: Sarepta Therapeutics (SRPT), Schrodinger (SDGR)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), ...
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...
Nasdaq7d
First Week of SRPT April 17th Options Trading
Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading this week, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...